Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines

Cancer Research

Volumn 62, Issue 1, 2002, Pages 313-322

  Crawford, Keith W ^a   Bowen, Wayne D ^b  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CASPASE INHIBITOR; CB 184; CB 64D; DACTINOMYCIN; DOXORUBICIN; HALOPERIDOL; LACTATE DEHYDROGENASE; LIGAND; LIPOCORTIN 5; OPIATE AGONIST; PROTEIN P53; SIGMA 2 OPIATE RECEPTOR; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL DEATH; CELL TYPE; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME RELEASE; GENOTYPE; HUMAN; HUMAN CELL; NICK END LABELING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DENSITY; STAINING; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZYLIDENE COMPOUNDS; BREAST NEOPLASMS; CASPASES; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DNA DAMAGE; DRUG SYNERGISM; HALOPERIDOL; HUMANS; LIGANDS; MORPHINANS; RECEPTORS, SIGMA; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036141493     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Sigma receptors: Biology and function
2. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems
3. The sigma receptors
4. A sigma-like binding site in rat pheochromocytoma (PC12) cells: Decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that in guinea pig brain
5. A proposal for the classification of sigma binding sites
6. Rat liver and kidney contain high densities of sigma-1 and sigma-2 receptors: Characterization by ligand binding and photoaffinity labeling
7. Purification, molecular cloning, and expression of the mammalian sigma 1-binding site
8. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines
9. Sigma-2 receptors as potential biomarkers of proliferation in breast cancer
10. Characterization of sigma receptor binding sites in human biopsied solid breast tumors
11. A malignant melanoma imaging agent: Synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)-4-iodobenzamide
12. 125I]BP: A potential sigma receptor marker for human prostate tumors
13. Cytotoxic effects of sigma ligands: Sigma receptor-mediated alterations in cellular morphology and viability
14. Sigma-2 receptor agonists induce apoptosis in rat cerebellar granule cells and human SK-N-SH neuroblastoma cells
15. The neurotoxic effect of iboga alkaloids may be mediated by sigma-2 receptors
16. Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture
17. ++]i in colon and mammary carcinoma cells
18. Relationship of sigma-2 receptor-mediated increases in intracellular calcium to induction of morphological changes and apoptosis in human SK-N-SH neuroblastoma cells
19. Modulation of cellular calcium by sigma-2 receptors: Release from intracellular stores in human SK-N-SH neuroblastoma cells
20. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest
21. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni-like family members
22. Clinical implications of p53 mutations
23. Cytometry in necrobiology: Analysis of apoptosis and accidental cell death (necrosis)
24. Exposure of phosphatidyl serine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages
25. Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors
26. CB-64D and CB-184: Ligands with high sigma-2 receptor affinity and subtype selectivity
27. Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells
28. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells
29. Resistance of MCF-7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function
30. In vitro evaluation of p53-expressing adenovirus as an anti-cancer drug
31. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
32. Caspases. The executioners of apoptosis
33. Inhibition of human caspases by peptide-based and macromolecular inhibitors
34. Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis
35. Resistance to apoptosis correlates with a highly proliferative phenotype and loss of Fas and CPP32 (caspase-3) expression in human leukemia cells
36. Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a FAS-independent way
37. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis
38. Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells
39. Caspase-3 is required for α-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis
40. An alternative, non-apoptotic form of programmed cell death
41. 2+-independent sphingomyelinase activities precede commitment to apoptosis and are not a consequence of caspase-3-like activity in Molt-4 cells in response to thymidylate synthase inhibition by GW1843
42. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by be1-2 but does not involve known caspases or p53
43. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis
44. 2+-induced apoptosis through calcineurin dephosphorylation of BAD
45. N-terminus cleavage of be1-2 by a novel cellular non-ICE cysteine proteinase
46. PML induces a novel caspase-independent death process
47. Molecular characterization of mitochondrial apoptosis-inducing factor
48. BAX-induced cell death may not require interleukin 1β-converting enzyme-like proteases
49. The c-myc-interacting adaptor protein BinI activates a caspase-independent cell death program
50. Investigation of bax-induced release of cytochrome c from yeast mitochondria: Permeability of mitochondrial membranes, role of VDAC and ATP requirement
51. Sigma receptors in the brain-endocrine-immune axis
52. MCF-7 breast-cancer cells overexpressing transfected c-erb B-2 have an in mitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen sensitivity in vivo
53. erb B-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
54. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer
55. Sigma receptor ligands modulate expression of the multi-drug resistance gene in human and rodent brain tumor cell lines
56. Computer-assisted analysis of binding data